Sun Pharma Announces Closure of Merger Deal with Ranbaxy
Sun Pharmaceutical Industries has begun the integration of Ranbaxy’s business following the successful
closure of its merger. The integration will focus on supporting strong growth. The merger has fortified Sun Pharma’s position as the world’s fifth largest specialty generic pharmaceutical company and the top ranking Indian Pharma company with significant lead in market share.
The combined entity’s manufacturing footprint covers five continents with products sold in over 150 nations with a stronger presence in US, India, Asia, Europe, South Africa, CIS & Russia and Latin America. Sun Pharma now offers a large basket of specialty and generic products encompassing a broad range of chronic and acute prescription drugs, as well as a ready foray into the global consumer healthcare market. Post-merger, Daiichi Sankyo becomes the second largest shareholder in Sun Pharma and both companies will work together to leverage this relationship for global business growth. The integrated culture theme, “Growing Together”, represents the core objective of this merger focusing on improving productivity, compliance commitment, focus on quality and sustainable growth. Through this merger Sun Pharma emerges as India’s first truly global pharmaceutical company.
The combination allows Sun Pharma to
1. Significantly expand its R&D capabilities and global presence, especially across emerging markets
2. Enhance product portfolio and market depth in India, US as well as Rest of the World markets
3. Improve strategic flexibility, ability to pursue partnerships and strengthen M&A bandwidth.
Following the closure of this transaction, Ranbaxy will be delisted from the Indian Stock Exchanges. Ranbaxy
shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. On pro forma basis for 12 months
ended December 2014, Sun Pharma’s gross margin stands at 76% (Industry average 62%); EBIDTA margin at
32% (industry average 19%) and Net margin at 20% (Industry average 12%).
Mr Israel Makov, Chairman, Sun Pharma said: “The combined entity will capitalize on the expanded globalfootprint and enhance our dominance as a world leader in the specialty generics landscape. Sun remainscommitted to uncompromised product quality, 100% compliance and promotes innovation to create the mostdynamic global specialty generics pharmaceutical company. We believe that our shareholders, customers and employees will share our excitement in the potential of this combination and thank them for their continued support.”
TOP PRIORITIES FOR COMBINED ENTITY
Sun Pharma has identified three key priority levers to drive growth in the combined entity:
1. Achieving 100% compliance in manufacturing in line with Regulator expectations
2. Increase R&D productivity to introduce new innovative products
3. Strong business growth across US, India, and Rest of the World markets.
Commenting on the combined entity’s priorities, Mr Dilip Shanghvi, Managing Director, Sun Pharmafurther added: "It is an important milestone in the history of Sun Pharma as we enter into a new phase ofgrowth. We will continue to focus on gaining trust of the Regulators globally while continuing to develop productsbased on patient needs and leverage them to become brand leaders globally.”
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe...
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test.
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development.
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug.
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours.
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ...
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance